Pasi Jänne
帕西·亚内
MD, PhD
Director, Lowe Center for Thoracic Oncology; Professor of Medicine, Harvard Medical School洛韦胸部肿瘤学中心主任；哈佛医学院医学教授
👥Biography 个人简介
International leader in EGFR-mutant lung cancer and resistance to EGFR inhibitors. Identified the EGFR T790M gatekeeper mutation as the predominant mechanism of acquired erlotinib/gefitinib resistance and led pivotal trials of osimertinib, a third-generation EGFR inhibitor overcoming T790M resistance.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EGFR T790M Resistance and Osimertinib
Discovered EGFR T790M as the dominant mechanism of first-generation EGFR TKI resistance in NSCLC and co-led the clinical development of osimertinib (AZD9291), including pivotal AURA trials that led to FDA approval for T790M-positive NSCLC.
Representative Works 代表性著作
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
New England Journal of Medicine (2015)
Phase 1 AURA trial demonstrating remarkable clinical activity of osimertinib in T790M-positive NSCLC, establishing a new standard of care for resistant EGFR-mutant lung cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 帕西·亚内 的研究动态
Follow Pasi Jänne's research updates
留下邮箱，当我们发布与 Pasi Jänne（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment